Andere Sprachen HOOKIPA Pharma Inc.

Aktien

A2PGMT

US43906K1007

HOOK

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 16.04.2024			% 5 Tage	% 1. Jan.
0,8099 ^USD	+6,57 %		-3,74 %	-0,01 %

10.04.	HOOKIPA Pharma Inc. gibt bekannt, dass die Europäische Arzneimittelagentur (EMA) dem Prüfpräparat HB-200 den PRIME-Status verliehen hat	CI
22.03.	HOOKIPA Pharma Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	16.04.
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration	10.04.
HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	10.04.
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	25.03.
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.03.
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.03.
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22.03.
North American Morning Briefing : Stocks Struggle After New Records	22.03.
North American Morning Briefing : Stock Futures -2-	13.03.
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference	06.03.
HOOKIPA Pharma to Cut 30% of Workforce in Restructuring	29.01.
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs	29.01.
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs	29.01.
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	17.01.
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	16.01.
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization	16.01.
HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024	16.01.
Top Premarket Gainers	21.12.
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences	21.12.
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences	21.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen HOOKIPA Pharma Inc.

Aktien

A2PGMT

US43906K1007

HOOK

Andere Sprachen

Filter